The prognostic significance of major organ and tissue infection was examined in 909 episodes of bacteremia that were selected from 10 consecutive, randomized clinical trials of antibiotic therapy for infection in patients with cancer and neutropenia. Extensive tissue infection significantly compromised response to initial therapy (38% vs. 74%; P õ .0001), ultimate outcome of infection (73% vs. 94%; P õ .0001), median time to normalization of temperature (5.3 days vs. 2.5 days; P õ .0001), and survival (P õ .0001). Other poor prognostic factors revealed by logistic regression included shock (P õ .0001) and bacteremia caused by Pseudomonas species (P Å .03), Clostridium species (P Å .006), or a pathogen resistant to antibiotics used for initial therapy (P õ .0001). Recovery of the granulocyte count predicted a superior response (P õ .0001). Although the overall mortality rate was not significantly increased when patients with bacteremia due to gram-negative organisms initially received monotherapy or when patients with bacteremia due to gram-positive organisms received delayed vancomycin therapy, these strategies increased the duration of therapy by 25%. Patients with bacteremia due to a-hemolytic streptococcus died more often when vancomycin was not included in the initial empirical regimen (P Å .004). Because of the prognostic significance of extensive tissue or major organ infection, this factor should be considered in decisions concerning modification of therapy and use of colony-stimulating factors. The cost-effectiveness of initial monotherapy and delayed vancomycin therapy remains to be demonstrated.
Infections in the patient with cancer and neutropenia are
Patients and Methods often characterized by the lack of significant clinical findPatients with bacteremia were selected from 10 consecutive, ings during physical examination and a clear focus of infecrandomized clinical trials of front-line antibiotic therapy for tion, perhaps because of the inability to mount an adequate febrile episodes in neutropenic patients with cancer between inflammatory response. However, our examination of the 1980 and 1993. Reports of the individual studies were preepidemiology of bacteremia in immunocompromised paviously published [14 -23] . There were no substantive differtients with cancer [1 -13] and our observation of the outences in eligibility requirements among the various studies. comes of bacteremia in patients treated in randomized antiPatients with fever (temperature to §38.3ЊC) that was unrelated biotic trials [14 -23] suggested that major organ infection to pyrogenic agents and persisted for at least 2 hours were and extensive tissue involvement do occur and that their considered eligible for the trials if they had no serious abnorpresence significantly influences the prognosis of neutromalities in either renal function (serum creatinine level, õ1.2 penic patients with bacteremia. Individual clinical trials mg/dL) or hepatic function (serum transaminase levels, less rarely include a sufficient number of episodes of bacteremia than five times the normal), were older than 16 years of age, to permit subgroup analyses of prognostic factors. Thus, and were not pregnant, lactating, or allergic to the study drugs. we report an analysis of the outcomes of 909 episodes of
The original clinical trials were conducted on hematology, bone bacteremia encountered during 10 randomized clinical trials marrow transplant, and medical oncology services; thus, virtuof initial empirical therapy for febrile neutropenia, with ally all patients had received either chemotherapy or immunoparticular emphasis on the prognostic significance of major therapy. organ and tissue involvement.
For this analysis, all patients without bacteremia, 48 nonneutropenic patients with bacteremia, and 17 patients whose initial antibiotic regimens were terminated because of an adverse reac-Blood cultures were processed according to the method of on the basis of results of cultures and susceptibilities. Treatment for patients whose initial therapy required modification was Cowan and Steele [24] . The in vitro susceptibilities of the causative pathogens to the initial antibiotics were tested by considered a failed initial antibiotic regimen.
Patients with bacteremia were categorized with respect to using the microtiter broth dilution method (Dynateck MIC 2000, Dynateck Laboratories, Alexandria, VA) according to the the extent of tissue invasion (either simple or complex) at the onset of infection. Complex bacteremias were defined as those guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) at the time that the clinical trial was conincluding infection of major organs (lungs, liver, spleen, kidneys, colon, bones, joints, veins, heart, and meninges), softducted. Because of changes in the dilutions recommended by the NCCLS since 1980, not all reported MICs correspond to tissue wound infection, abscess, or cellulitis that was ú5 cm in size and found during physical examination, or soft-tissue the current guidelines. Methicillin susceptibility of staphylococci and penicillin susceptibility of streptococci were tested infection (of any size) with necrosis. Thus, superficial softtissue infections without necrosis and those infections (includby using the Kirby-Bauer disk method [25] .
ing phlebitis) with sizes of õ5 cm, cystitis, bacteriuria, and nonsuppurative pharyngitis or otitis were considered simple Definitions infections. The choice of 5 cm was based on a review of the relationship between size of lesions and outcomes of 163 cases Patients were considered neutropenic if their absolute neutrophil count at the onset of therapy was õ1,000/mm 3 or fell of nonbacteremic soft-tissue infections in the same clinical trials. Among the nonbacteremic patients with soft-tissue lebelow that level in the 2 days following initiation of therapy. Neutrophil counts were further categorized according to sions with sizes of ú5 cm, the rate of response to initial therapy was 43% compared with 87% among patients with smaller whether they were õ100/mm 3 at the onset of therapy. Shock was defined as a systolic blood pressure of õ90 mm Hg (in a lesions (P õ .0001). For this analysis, patients without an identifiable focus of previously normotensive patient) at the onset of bacteremia. There were no cases of septic shock occurring after the onset infection were combined with patients with simple infections because they were virtually identical demographically, progof bacteremia (ú24 hours after the first temperature of §38.3ЊC) in this study. Episodes of polymicrobial bacteremia nostically, and microbiologically. were those in which more than one organism was isolated from one or more blood cultures within a 72-hour period. Organisms
Statistical Considerations
not shown to be susceptible in vitro to the initial antibiotics administered were considered resistant, which included both This study is a secondary analysis of data collected during prospective clinical trials. The patients were followed prospec-''intermediate'' and ''resistant'' categories.
Five outcomes for each patient were measured: response to tively during the initial clinical trials by study personnel whose primary responsibilities were management of the infectious the initial antibiotic regimen, ultimate outcome of infection, time to normalization of body temperature (computed as the episodes according to standardized protocols and collection of data in a standard format. During the clinical trials, the original number of days between the onset of antibiotic therapy and the return of temperature to õ37.8ЊC), duration of antibiotic data were entered into a computerized database that was used as the primary data source for this study. Thus, our data are therapy, and duration of survival (from the onset of antibiotic therapy). Response to antibiotic therapy was defined as comnot subject to underreporting or poor documentation as would be the case with a retrospective review of medical records. plete resolution of all clinical and microbiological signs and symptoms of infection except in cases of pneumonia. In these Twenty-one variables were examined for prognostic significance. These variables included demographic variables (age cases, response was defined as resolution of all symptoms, negativity of all cultures, and significant improvement demonand gender), factors related to the underlying malignancy (cancer diagnosis and bone marrow transplantation), clinical feastrated by chest roentgenography [26] . Response to initial antibiotic therapy, designated as initial response throughout the tures (shock; initial levels of serum creatinine, albumin, bilirubin, and serum transaminases; and neutrophil count and trend article, was determined at the point at which the initial regimen was either discontinued or amended. Ultimate outcome of antiduring therapy), infection variables (associated site of infection, size of soft-tissue lesions, necrosis, organism, and susceptibilbiotic therapy was determined at the end of all antibiotic therapy. All patients for whom therapy was classified as an ultimate ity), and treatment variables (initial regimen, number of antibiotics, vancomycin use, and schedule of antibiotics). failure died of infection. Treatment for those patients whose course was prolonged but who eventually responded to antibiDifferences between categorical variables were tested for significance by using two-tailed Pearson's x 2 tests (or Fisher's otic therapy was considered an ultimate response.
All patients were evaluated daily during antibiotic therapy. exact test when appropriate). Those differences between continuous variables were tested by using the Mann-Whitney test. At 48 to 72 hours, therapy for patients whose conditions had clinically deteriorated was modified at the discretion of the Analysis of the duration of survival and time to response were done by using the Kaplan-Meier method. attending physician. Antibiotics for modification were chosen Figure  neoplasms was similar to that among the remainder of patients, as was the proportion who had undergone bone marrow trans-1 as odds ratios and 95% confidence limits. All analyses were computed by using BMD/Dynamic statistical software (BMDP, plantation (35% vs. 21%, respectively; P Å .24). West Los Angeles).
Microbiology

Results
Gram-positive organisms caused 46% of bacteremias, gramnegative organisms caused 42% of bacteremias, and 12% of In the 10 clinical trials, 909 episodes of bacteremia occurred in 799 patients. Seventy-nine patients had 2 episodes, 9 had 3 bacteremias were polymicrobial ( tively; P Å .03) compared with patients with all other bacterisolates were resistant to methicillin. Among patients with bacteremia due to coagulase-negative Staphylococcus, the rate of emias due to gram-negative organisms (table 1) . A similar pattern was observed for patients with bacteremia caused by response to initial therapy was lower during episodes caused by methicillin-resistant organisms (55%) than during those Enterobacter species. The lower response rates observed among these patients were not due to resistance to the initial caused by methicillin-susceptible organisms (73%; P Å .06). A similar pattern was observed among patients with bacteremias antibiotics, which was rare, but rather to the increased frequency of complex infections (particularly pneumonia and caused by a-hemolytic Streptococcus; 91% of patients with bacteremias caused by penicillin-susceptible organisms reperirectal infection) compared with all other bacteremias due to gram-negative organisms (30% vs. 16%, respectively; sponded to the initial regimen compared with only 65% of those with bacteremias caused by penicillin-resistant organisms P Å .003).
Although the overall proportion of patients with complex (P Å .004). However, ultimate outcome did not differ significantly between patients with bacteremia caused by penicillininfections due to gram-negative organisms (17%), gram-positive organisms (15%), and multiple organisms (17%) was simisusceptible or -resistant organisms or methicillin-susceptible or -resistant organisms. lar, differences were observed for some species (table 1) . For example, õ15% of bacteremias caused by coagulase-negative For bacteremias caused by each of the gram-negative organisms, response by simple infections was significantly superior Staphylococcus, Klebsiella species, or a-hemolytic Streptococcus were complex, while the proportion of complex infections to that by complex infections, regardless of the specific organism (P õ .05 for all comparisons). This observation was true due to pneumococci, Staphylococcus aureus, or P. aeruginosa was ú24%.
for response to initial therapy as well as for ultimate response to therapy. A similar pattern was observed for polymicrobial Resistance to methicillin was uncommon (3%) in S. aureus isolates; however, 62% of coagulase-negative ), among whom a 23% difference in response rates was observed between those Associated Sites of Infection whose neutrophil counts recovered (86%) and those whose Infection at a site other than the bloodstream was identified neutrophil counts were unchanged (63%; P Å .04). Response in 242 episodes. Of these episodes, 104 were simple infections, rates among profoundly neutropenic patients with simple bacand 138 were complex infections. The response rate among teremias were dramatically higher than those among patients patients without other evidence of infection was similar to that with complex bacteremias (94% vs. 70%, respectively; P õ among patients with simple infections (94% vs. 98%, respec-.001), and even the response rate among those patients with tively; P Å .14) (table 2). Not surprisingly, patients with comsimple bacteremias who remained profoundly neutropenic at plex infections fared more poorly than did those with simple the end of antibiotic therapy was 92%. infections with respect to initial therapy (38% vs. 74%, respectively; P õ .0001) as well as ultimate response to therapy (73% vs. 94%, respectively; P õ .0001). Overall, the lowest ultimate Prognostic Factors response rate (75%) was observed among patients with pneuAntibiotic therapy for patients with complex bacteremias monia, whereas the ultimate response rates observed among was far more likely to fail than was that for patients with simple most of the remaining patients exceeded 80%. All 49 patients bacteremias (table 4) . Rates of response to initial therapy with simple soft-tissue lesions smaller than 5 cm in size reamong patients with simple bacteremias exceeded those among sponded compared with only 63% of those with complex lepatients with complex bacteremias by ú35%. Furthermore, the sions exceeding 5 cm in size (P õ .0001). Response rates disproportion between the response rates associated with simincreased 20% among patients with simple infections and 35% ple and complex bacteremias persisted even after modification in patients with complex bacteremias after modification of the of initial therapy (94% vs. 73%, respectively; P õ .0001). initial regimen.
The presence of shock at the onset of bacteremia was an ominous clinical sign. The rate of response to the initial antibi-
Impact of Neutrophil Count
otic regimen among patients with shock was only 35% compared with 70% among patients without shock (P õ .0001). Response rates among patients whose neutrophil counts increased were greater (96%) than those among patients whose More importantly, because of the fulminant nature of these infections, only two of the 22 patients with shock for whom The rate of response to the initial empirical antibiotic regimen among patients with bacteremias caused by resistant orinitial therapy failed survived long enough to permit modification of therapy and subsequent response. Considering the disganisms was low (50%) when compared with that among those with bacteremias caused by susceptible organisms (70%) mal response rates among patients with shock, it is fortunate that this finding was relatively uncommon, particularly among (P Å .004) (table 4) . However, this difference decreased to õ10% in ultimate response rates after time had permitted identification patients with bacteremias due to gram-positive organisms (1%). However, 5% of patients with bacteremias due to gram-negaof the pathogen and appropriate modification of therapy.
Rates of response to initial antibiotic therapy were lower tive organisms and 10% of those with polymicrobial bacteremias presented in shock. Only 3% of patients with simple among patients who received bone marrow transplants than among those who did not (59% vs. 71%, respectively; bacteremias presented with shock compared with 10% of patients with complex bacteremias (P õ .0001).
P Å .002); however, this difference was reduced to only 4% / 9c38$$au46 07-21-97 14:10:55 cida UC: CID in ultimate response rates. A similar pattern was observed when time, 79% received ciprofloxacin prophylaxis, and the remainder received trimethoprim-sulfamethoxazole prophylaxis. rates of response to initial therapy were compared between patients with leukemia (63%) and patients with solid tumors There were no differences in outcome or in the frequency of either complex bacteremia or bacteremia due to resistant (77%; P Å .0002). Again, the disparity in response rates was largely eliminated when ultimate response rates were assessed.
organisms between patients who received prophylaxis and those who did not receive prophylaxis. Patients older than 50 years of age responded significantly more frequently to initial therapy than did their younger counAmong patients with bacteremias due to gram-negative organisms, the rate of response to initial regimens containing two terparts (73% vs. 64%, respectively; P Å .006); this finding was perhaps due to the relative frequency of acute leukemia drugs was superior to that of single-drug regimens (82% vs. 67%, respectively; P Å .001), whether the regimen contained and aggressive therapy (such as bone marrow transplantation) among younger patients (table 4) . Ultimate outcome of infectwo b-lactam drugs (82%) or a b-lactam agent plus an aminoglycoside (83%) (table 5). The exceptions to this pattern were tion was not related to age.
The prognostic significance of major organ or tissue infection patients who received single-agent therapy with aztreonam, cefoperazone/sulbactam, or imipenem, among whom initial is clearly illustrated by the differing survival rates among the two groups of patients (figure 2). By the third week of infection, rates of response approached those to two-drug regimens (76%, 84%, and 79%, respectively). Despite the initial superiority of only 5% of patients with simple infections had died compared with 20% of patients with complex infections (P õ .0001).
two-drug regimens, a strategy consisting of initial single-drug therapy followed by the addition of a second drug for nonAntibiotic therapy not only failed for patients with complex bacteremias more frequently than did that for those with simple responders resulted in ultimate response rates (90%) that were identical to those among patients who received two-drug regiinfections, but also those patients who responded required more days of therapy to become afebrile. For example, the median mens from the outset of therapy. It is important to note, however, that the mean duration of therapy for patients who retime to normalization of temperature in patients with simple bacteremias was one-half that observed for patients with comceived single-drug regimens initially was 8.9 days compared with only 7.2 days for their counterparts who received twoplex bacteremias (2.5 vs. 5.3 days, respectively; P õ .0001). The extended duration of fever was associated with a corredrug regimens from the onset of bacteremia (P Å .03). Considering only those patients with bacteremias due to sponding increase in the duration of antibiotic therapy. The mean duration of therapy for patients with simple bacteremias gram-negative organisms who initially received a single drug with activity against gram-negative organisms (table 5) , therwas 7.8 days compared with 10.5 days for those with complex bacteremias (P õ .0001).
apy with aztreonam, cefoperazone/sulbactam, or imipenem was far superior to that with ceftazidime, piperacillin, or ticarcillin/clavulanate (81% vs. 52%, respectively; P õ
Impact of Antibiotic Regimens
.0001). This difference persisted even when only those episodes caused by susceptible organisms were considered In 46% of episodes, prophylactic antibacterial antibiotics (85% vs. 67%; respectively; P Å .009). Although the addiwere administered immediately before the onset of bacteremia.
tion of a second drug to the monotherapy regimens improved Before 1988, most patients (88%) who received prophylactic the ultimate outcome, a statistically significant difference in antibiotics received trimethoprim-sulfamethoxazole. Since that ultimate outcome persisted between patients receiving aztreonam, cefoperazone/sulbactam, or imipenem and those receiving ceftazidime, piperacillin, or ticarcillin/clavulanate (94% vs. 85%, respectively; P Å .04). Lower rates of response to the initial antibiotic were observed among patients with complex bacteremias (table 5). Initial response rates among patients with complex bacteremias were uniformly poor regardless of which regimen was received, the only possible exception being the response of six of seven patients to initial therapy with cefoperazone/sulbactam. However, this finding is difficult to interpret because of the small sample size.
A variety of therapy modifications were used for patients with bacteremia due to gram-negative organisms for whom initial therapy failed primarily on the basis of the susceptibility NOTE. Data represent total number of patients (percent of patients who responded to treatment). Response to modification Å total no. who received modification (percent responses to modification); susc org Å bacteremias in which the organism was susceptible to all antibiotics received (for infections due to gram-negative organisms, susceptibility to aminoglycosides and/or b-lactam agents; for infections due to gram-positive organisms, susceptibility to vancomycin and/or b-lactam agents); ultimate response Å total no. of patients (percent of total no. of responses to any therapy).
* P Å .54.
was often added to or replaced therapy with initially ineffective entirely attributable to a-hemolytic streptococcus bacteremias in patients who did not receive vancomycin as a part of the b-lactam antibiotics).
Patients with simple bacteremias due to gram-positive organinitial empirical regimen. All 52 patients with a-hemolytic streptococcus bacteremia isms responded more frequently to initial regimens including vancomycin than did those without these infections (86% vs.
who received initial vancomycin compared with only 86% of 65 patients with a-hemolytic streptococcus bacteremia 49%, respectively; P õ .0001) (table 5). However, the subsequent addition of vancomycin resulted in a 90% ultimate rewhose vancomycin therapy was delayed survived their infection (P Å .004). All a-hemolytic streptococci causing fatal sponse rate, compared with 97% among patients who received vancomycin initially (P Å .01). Combining all simple and combacteremias were susceptible in vitro to both the initial antibiotic regimen and to vancomycin (table 6), although two plex bacteremias, the difference in ultimate response rates between patients with bacteremia due to gram-positive organisms of the organisms were only moderately susceptible to the initial b-lactam antibiotic and one was resistant to penicillin. who received initial regimens including vancomycin (94%) and those whose regimens were modified with vancomycin (90%)
Only one of the patients had evidence of tissue infection, and all but one received at least 6 days of vancomycin therdid not reach statistical significance (P Å .20). However, the excess mortality rates associated with simple bacteremias were apy after treatment modification. Six of the nine patients / 9c38$$au46 07-21-97 14:10:55 cida UC: CID NOTE. AML Å acute myelogenous leukemia; ANC Å absolute neutrophil count; BMT Å bone marrow transplantation; R Å resistant; S Å susceptible. * Susceptibility of the organism to the b-lactam antibiotic in the initial regimen (moxalactam, imipenem, or ceftazidime). † Disk diffusion technique. ‡ This patient was treated in an early trial of ceftazidime during which time different microtiter dilutions were recommended by the National Committee for Clinical Laboratory Standards (NCCLS). This value is roughly equivalent to 16 mg/mL using current NCCLS dilutions.
with fatal streptococcal bacteremias received ceftazidime received vancomycin therapy at the onset of bacteremia was only 8.6 days compared with 11.8 days for patients whose initially. All of the patients were profoundly neutropenic for a prolonged period, and all but three had either acute leukevancomycin therapy was delayed (P Å .01).
Initial response by patients with complex bacteremias due mia or had undergone bone marrow transplantation.
The characteristics of the patients with fatal a-hemolytic to gram-positive organisms was poor regardless of whether vancomycin was included initially in the regimen. However, streptococcus bacteremia were not unlike those of the other patients with a-hemolytic streptococcus bacteremia, 100% of response rates increased significantly by ultimate assessment of outcome. Most (70%) of the patients for whom therapy whom responded to initial regimens including vancomycin. They differ from most patients with a-hemolytic streptococcus ultimately failed had S. aureus bacteremia complicated by either pneumonia or large, necrotic soft-tissue infections. Modibacteremia who ultimately responded to therapy in that their infections occurred before mid-1988, at which time the increasfication of therapy with either rifampin or a penicillin plus gentamicin was used for patients with bacteremias due to graming clinical significance of this infection in patients with cancer was recognized in our institution. Although vancomycin was positive organisms for whom therapy with vancomycin failed. The inclusion of vancomycin in treatment resulted in a 35% -added to treatment in every case, the deteriorating clinical course was often assumed to be caused by other pathogens, 40% increase in the rate of response to the initial regimen regardless of which other antibiotics were used (table 5) . Most particularly fungi. Only one of these patients received penicillin and gentamicin. In contrast, patients with a-hemolytic streptoorganisms were sensitive in vitro to both vancomycin and the other agents used. Thus, response rates among patients with coccus bacteremias that occurred in subsequent years received initial regimens that included vancomycin and modification bacteremia due to susceptible organisms were virtually identical to those observed in overall comparisons. When considering with penicillin ( §4,000,000 U/d) plus gentamicin if their condition did not improve clinically after 48 -72 hours of vancoonly those infections in which the organism was susceptible to all drugs administered, the rate of response to initial regimens mycin therapy. This strategy has virtually eliminated deaths in patients with a-hemolytic streptococcus bacteremias in clinical with two b-lactam agents was somewhat higher (72%) than the rates of responses to regimens with either a single b-lactam trials. However, it is not clear whether this improvement in prognosis was achieved by empirical use of vancomycin from agent (45%; P Å .08) or an aminoglycoside plus a b-lactam agent (53%; P Å .18), although these differences did not reach the initiation of febrile episodes or by modification with penicillin plus gentamicin for patients for whom initial vancomycin statistical significance. In 23 episodes of simple bacteremia due to gram-positive therapy failed.
The predominance of failures of therapy for a-hemolytic organisms and six episodes of complex bacteremia due to grampositive organisms, antibiotic therapy was supplemented by streptococcus bacteremias suggests caution in interpreting the similar response rates in overall comparisons and complicates removal or exchange of the central venous catheter. The organism causing bacteremia was cultured from the tip of the catheter the question of whether vancomycin should be included in initial regimens. Furthermore, the mean duration of therapy for in 14 (61%) of the simple episodes and two (33%) of the complex episodes. However, because a variety of catheter manpatients with bacteremias due to gram-positive organisms who / 9c38$$au46 07-21-97 14:10:55 cida UC: CID agement strategies were used for these patients, it is impossible random sample of all bacteremic patients during the years studied. Since patients were selected for the original clinical trials to determine both the true frequency of catheter-related bacteremias and the benefit of removing the catheter for these on the basis of clinical stability and adequate renal and hepatic function, selection bias in favor of patients with improved progpatients.
noses is likely. Furthermore, the trials were not conducted on surgical oncological services; thus, patients with postsurgical
Multiple Variable Prognostic Models bacteremia are not represented in the sample. (This source of bias is probably minimal since the study is limited to patients Because of the multifactorial nature of the outcome of bacteremia, the unique effect of each factor on outcome was examwith granulocytopenia, an uncommon condition in patients following surgery.) Therefore, the results should not be interpreted ined in a multiple variable model. This analysis revealed that initial regimens containing two active drugs (P Å .0003) and to represent a model of bacteremia in all granulocytopenic patients with cancer but rather only those who would meet the those containing vancomycin administered to patients with bacteremias due to gram-positive organisms (P õ .0001) were clinical stability requirements for enrollment in clinical trials of antibiotics. associated with a superior initial response ( figure 1) . Recovery of the neutrophil count by the end of the second day of therapy (when response to initial therapy was typically assessed) was Prognostic Significance of Complex Bacteremias also associated with an improved outcome (P Å .09).
The presence of shock (P õ .0001), complex bacteremia Bacteremia in immunocompetent hosts is often the result of dissemination of a previously localized tissue infection. For (P õ .0001), an underlying diagnosis of leukemia (P õ .0001), and infection with an organism resistant to the antibiotics rethis reason, the development of bacteremia following deeptissue infection has been considered an ominous clinical sign ceived (P Å .002) were associated with an increased risk of failure. Patients with bacteremias caused by b-hemolytic Strepand a marker for poor outcome. One of the many examples of this phenomenon is provided by the twofold increase in the tococcus, Listeria species, Clostridium species, and other grampositive anaerobes were also at increased risk for therapy failmortality rate that is associated with bacteremic pneumococcal pneumonia compared with pneumococcal pneumonia alone ure. It is interesting that initial antibiotic therapy for patients with decreased serum albumin levels at the onset of bacteremia [37] . In contrast, bacteremia in immunocompromised patients may be the result of the entry of endogenous flora originating was almost three times more likely to fail (P Å .0009).
The presence of shock was the single most important factor from the gastrointestinal tract into the bloodstream. These bacteremias most commonly occur without clinical evidence of in predicting ultimate outcome of infection (figure 1). Patients with shock were ú20 times more likely to die of infection deep-tissue infection and are successfully treated in ú90% of cases. In this population, deep-tissue infection may often be than their counterparts without shock (P õ .0001). Complex bacteremia and an abnormally low serum albumin level at the the result of hematogenous spread of infection rather than its cause and, as such, may be as indicative of extension of infeconset of bacteremia were also significantly associated with poorer outcomes (P õ .0001 and P Å .02, respectively). Pation as the development of bacteremia in the normal host. We suggest that it is deep-tissue infection in immunocompromised tients with bacteremia caused by either Pseudomonas species (P Å .03) or Clostridium species (P Å .006) were also at patients rather than bacteremia that is associated with poor prognosis. increased risk for therapy failure. Recovery of the neutrophil count at the time when ultimate outcome was assessed exerted Although these tissue infections occur in only 15% of neutropenic patients with cancer and bacteremia, it is clear from our a highly protective effect on outcome (P õ .0001).
data that the presence of extensive tissue infection significantly influences response to therapy and survival. In fact, in the trials Discussion included in this analysis, the response rates among patients with bacteremia complicated by either pneumonia (42%) or The prognostic models constructed from analysis of these 909 episodes of bacteremia are consistent with prior reports soft-tissue infection (63%) more closely resembled those observed among patients with either pneumonia alone (54%) or demonstrating the prognostic significance of shock, resistant organisms, hematologic malignancies, and recovery of the soft-tissue infection alone (67%) rather than those observed among patients with bacteremia alone (73%). These findings granulocyte count [27 -33] . The change in the relative frequencies of bacteremias due to gram-negative and gram-positive suggest that reports of antibiotic trials focusing only on bacteremic patients may overestimate the efficacy of antibiotic regiorganisms has also been reported in other centers [34 -36] . The consistency of these findings underscores the representativemens by removing nonbacteremic deep-tissue infections from analysis and reserving for analysis many relatively responsive ness of our sample of patients, the relevance of our data to other centers, and the broad generality of our results. simple bacteremias. Furthermore, the frequency and response rates associated with deep-tissue infection complicating bacterOn the other hand, this sample of patients was selected from subjects enrolled in clinical trials of antibiotics and was not a emia should be routinely included in reports of trials of antibi-/ 9c38$$au46 07-21-97 14:10:55 cida UC: CID otic therapy for immunocompromised patients with cancer in the multiple variable models led to several intriguing observations concerning the choice of effective regimens and interto obtain a good estimate of outcome of these most serious infections.
mediate outcomes, such as duration of fever and duration of therapy. We report these observations here as a prelude to Further evidence of the prognostic significance of tissue infection is provided by the 20% decrease in the survival rate future investigations. among patients with complex bacteremia whose neutrophil counts failed to recover by the end of antibiotic therapy. It is Antibiotic Regimen and Assessment of Outcome not surprising that recovery of the neutrophil count would have the greatest impact on patients in whom resolution of deepAs previously noted by other investigators [39, 40] , when broad-spectrum antibiotics are administered empirically at the tissue infection may be dependent on the activity of neutrophils. These findings suggest that the benefits of therapy with colonyonset of infection, no single regimen seems to be superior in treating bacteremias due to gram-negative organisms. Furtherstimulating factors should be explored for such patients. Regimens including colony-stimulating factors for patients with more, the initial use of a two-drug regimen does not result in increased survival. The initial superiority of a two-drug regineutropenia and pneumonia persisting beyond the fourth day of antibiotic therapy have been recommended by the American men over a one-drug regimen disappears when ultimate outcome is assessed. This finding supports several hypotheses. Society of Clinical Oncology Guidelines Committee [38] . This strategy could be beneficial for all persistently neutropenic paFirst, this finding could reflect attending physicians' lack of confidence in a one-drug regimen, resulting in a tendency to tients with complex bacteremias and should be tested prospectively in a randomized clinical trial. Conversely, considering modify single-agent regimens on less-stringent clinical indications. Another possibility is that a subset of bacteremic patients the extremely high response rate observed among profoundly neutropenic patients with simple bacteremias whose neutrophil require two-drug regimens and respond only after a second drug is added to treatment. Alternatively, patients receiving counts did not recover during antibiotic therapy (92%), it is unlikely that the use of colony-stimulating factors would protwo-drug regimens may respond more rapidly (not more frequently) than their counterparts receiving a one-drug regimen. vide sufficient additional benefit to justify their cost.
The number of days of fever was also significantly affected Continued fever at 48 hours, at which time the results of the initial blood cultures are available, is a common reason for by the presence of tissue or major organ infection. Although, this observation is confounded by the significant influence of modification of therapy for neutropenic patients with bacteremia. It is possible that clinically stable patients receiving sinthe recovery of the granulocyte count, it was an independent predictor in the multiple variable model. Thus, in clinical trials gle-antibiotic therapy might respond to the initial regimen if given another 24 -36 hours of therapy. However, patients enof antibiotic therapy for these patients, it may be appropriate to allow an additional 24 -36 hours for complex bacteremias rolled in clinical trials are managed according to standardized protocols to avoid bias, and allowance has not typically been to respond to initial therapy before treatment modification, providing of course that the patient's clinical condition has not made for special management of patients with infections with poorer prognoses. Such a strategy would have the advantage deteriorated. This strategy may permit a better assessment of the efficacy of the initial regimen for patients whose conditions of demonstrating the effectiveness of antibiotic regimens in these difficult-to-treat infections but the disadvantage of requirare stable.
Although our data demonstrate a clear association between ing separate statistical analysis of simple and complex infections and a corresponding increase in sample size. failure of initial therapy and the presence of deep-tissue infection, it is not possible to determine which is the cause and Finally, bacteremic patients receiving two-drug regimens may be less likely to develop complex tissue infection than which is the effect. From a clinical standpoint, it is also difficult to determine in some cases whether initial therapy failed betheir counterparts receiving single-drug therapy. In those cases in which tissue infections are the result rather than the cause cause patients had complex infections or, alternatively, whether patients developed deep-tissue infections while receiving lessof bacteremia, two-drug regimens may be more effective in preventing the extension of bacteremia to tissue involvement effective regimens. In this study, none of the patients developed bacteremia after pneumonia became clinically evident; howthan single-drug regimens. As previously discussed, this issue is complicated, and its resolution is not likely to be derived ever, in some cases, there was no radiological evidence of pneumonia until the second day of therapy. Unfortunately, this from observational studies. More importantly, even for patients whose bacteremias due to gram-negative organisms are compliobservation is confounded by the impact of recovery of the neutrophil count on the development of clinical and radiologicated by complex tissue infections, it appears that multipledrug therapy can be safely reserved for those who do not cal evidence of tissue infection; thus, resolution of the cause and effect question may be impossible without studies with an respond to single-antibiotic therapy. Similarly, initial vancomycin therapy for bacteremias due to animal model to examine the underlying pathology.
Although this study was not designed to compare the efficacy gram-positive organisms results in more rapid resolution of infection, but delaying vancomycin therapy for 48 hours until of the various antibiotic regimens, inclusion of this information / 9c38$$au46 07-21-97 14:10:55 cida UC: CID
